- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Carthage Today
By the People, for the People
Tylenol Makers Fight Texas AG's Autism Warning Label Case
Lawyers argue there is no scientific evidence to support the warning, while state says transparency is necessary for consumer safety.
Published on Feb. 13, 2026
Got story updates? Submit your updates here. ›
Lawyers for the makers of Tylenol are seeking to dismiss a case brought by Texas Attorney General Ken Paxton that would require the company to add warning labels about a potential link between the medication and autism or ADHD in children. The state argues that consumers have a right to be informed, while the company says the claims are not based in science and that label changes should be left to the FDA.
Why it matters
This case highlights the ongoing debate around consumer transparency and the role of state governments in mandating warning labels, even when federal regulators have not required them. It also touches on the tension between pharmaceutical companies' desire to protect their products and the public's right to be informed about potential health risks.
The details
In September 2025, the Trump administration announced a potential link between Tylenol use by pregnant women and young children and the development of autism and ADHD. Texas Attorney General Ken Paxton subsequently filed a case seeking to require Tylenol makers Johnson & Johnson and Kenvue to add warning labels about this potential connection. However, the companies' lawyers argue that the claims are not supported by scientific evidence and that label changes should be left to the FDA. They are seeking to have Paxton's case dismissed.
- In September 2025, the Trump administration announced a potential link between Tylenol use and autism/ADHD.
- In late 2025, Texas Attorney General Ken Paxton filed a case seeking to require Tylenol warning labels.
The players
Ken Paxton
The Attorney General of Texas who filed the case seeking Tylenol warning labels.
Johnson & Johnson
The maker of Tylenol, which is fighting the warning label case.
Kenvue
The maker of Tylenol, which is fighting the warning label case alongside Johnson & Johnson.
Kim Bueno
The attorney representing Tylenol makers Johnson & Johnson and Kenvue.
John Masslon
The attorney representing Texas Attorney General Ken Paxton.
What they’re saying
“We're defending this product and company against what we believe to be false claims by the State of Texas.”
— Kim Bueno, Attorney representing Tylenol makers (ktre.com)
“It's important that Texans are not being misled by big pharmaceutical companies and that's what's going on here. You have a big pharmaceutical company that is continuing to mislead Texans.”
— John Masslon, Attorney representing Texas Attorney General (ktre.com)
“It's just a shame for these types of claims to be brought for a label change that's not based in science. So that's why we're here.”
— Kim Bueno, Attorney representing Tylenol makers (ktre.com)
What’s next
The judge in the case will decide within 30 days whether to allow the case to move forward.
The takeaway
This case highlights the ongoing tension between consumer transparency and pharmaceutical companies' interests, as well as the role of state governments in mandating warning labels that go beyond federal requirements. The outcome could set a precedent for how such disputes are handled in the future.
